Watch RNA. Know when insiders buy.
One email the day a filing lands. Free.
RNA
Atrium Therapeutics, Inc.
8.02
+0.04 +0.56%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
60
WATCH · shorts 60
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
FINANCIALS: NOT YET PULLED FROM SEC XBRL, CHECK BACK AFTER TONIGHT52W 7.61 – 16.54
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $3M | — | — | −$22.6M | −$20.2M | — | -1.18 | −$3.9M | $36K | −$4M | Aug 13 |
| Q1 2026 · Mar 31 | $19.6M | — | — | −$17.3M | −$16.6M | — | -0.97 | −$31.1M | $2.1M | −$33.2M | Aug 13 |
| Q2 2025 · Jun 30 | $3.8M | — | — | −$12.9M | −$12.9M | — | -0.75 | −$11.9M | $266K | −$12.2M | Aug 13 |
| Q1 2025 · Mar 31 | $1.6M | — | — | −$7.5M | −$7.4M | — | -0.44 | −$11.1M | $0 | −$11.1M | Aug 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|
Every number comes from Atrium Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.